

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 to 5. (Cancelled)


(I)

R2 and R3 are, independently, selected from the group consisting of straight or branched chain lower alkyl groups (having 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon atoms), 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and

X<sup>-</sup> represents an anion associated with the positive charge of the N atom; such that the compound is a quaternary salt; and a pharmaceutically acceptable carrier or diluent suitable for dry powder oral inhalation; and wherein the method of contacting the receptor with the composition is via inhalation by the mouth of the mammal.

7. (previously presented) A method of inhibiting the binding of acetylcholine to a muscarinic acetylcholine receptor in the respiratory tract of a mammal in need thereof, wherein acetylcholine binds to said receptor, comprising contacting the M<sub>3</sub> muscarinic

acetylcholine receptor with an effective amount of a composition comprising a compound of Formula (I)



wherein:

R<sub>2</sub> and R<sub>3</sub> are, independently, selected from the group consisting of straight or branched chain lower alkyl groups (having 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon atoms), 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and

X<sup>-</sup> represents an anion associated with the positive charge of the N atom;

such that the compound is a quaternary salt; and a pharmaceutically acceptable carrier or diluent suitable for dry powder oral inhalation; and

wherein the method of contacting the receptor with the composition is via inhalation by the mouth of the mammal.

8. (Previously presented) A method according to claim 7 wherein the binding of the M<sub>3</sub> muscarinic acetylcholine receptor is useful in the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis.

9. (Previously presented) A method according to claim 7 wherein administration is via inhalation via the mouth from a medicament dispenser which is a reservoir dry powder inhaler.


10. (Previously presented) A method according to claim 7 wherein administration is via inhalation via the mouth from a medicament dispenser which is a multi-dose dry powder inhaler.

11. (Previously presented) A method according to claim 7 wherein the composition has a duration of action of 12 hours or longer and the mammal is a human.

12. (Previously presented) A method according to claim 11 wherein the composition has a duration of action is 24 hours or longer.

13. (Cancelled)

14. (Previously presented) A method of treating chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis in a human in need thereof, comprising administering to said human by inhalation via the mouth an effective amount of a composition comprising a compound of Formula (I)



wherein:

R<sub>2</sub> and R<sub>3</sub> are, independently, selected from the group consisting of straight or branched chain lower alkyl groups (having 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon atoms), 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and

X<sup>-</sup> represents an anion associated with the positive charge of the N atom;

such that the compound is a quaternary salt; and a pharmaceutically acceptable carrier or diluent suitable for dry powder oral inhalation.

15. (Previously presented) The method according to Claim 14 wherein the treatment is of chronic obstructive lung disease or asthma.

16. (Previously presented) The method according to Claim 14 wherein administration is via inhalation via the mouth from a medicament dispenser which is a reservoir dry powder inhaler.

17. (Previously presented) The method according to Claim 14 wherein administration is via inhalation via the mouth from a medicament dispenser which is a multi-dose dry powder inhaler.

18. (Previously presented) The method according to Claim 14 wherein the orientation of the alkyl chain attached to the tropane ring is endo.

19. (Previously presented) The method according to Claim 14 wherein the compound of Formula (I) is:

(3-endo)-3-(2-Hydroxy-2,2-di-2-thienylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;

(3-endo)-3-(2-Hydroxy-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;

(3-endo)-3-[2-Hydroxy-2-phenyl-2-(2-thienyl)ethyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;

(3-endo)-3-(2-Cyclohexyl-2-hydroxy-2-phenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;

(3-endo)-3-(3-Cyclohexyl-2-hydroxy-2-phenylpropyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;

(3-endo)-3-[2-Hydroxy-2-phenyl-2-(2-pyridinyl)ethyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; or

(3-endo)-3-(2-Hydroxy-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane 4-methylbenzenesulfonate.

20. (Previously presented). The method according to Claim 14 wherein X<sup>-</sup> is selected from the group consisting of chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate.